Bandai Namco have released their earnings and predictions forecast featuring Super Sentai, Kamen Rider, and Ultraman.

First quarter sales in the current fiscal year associated with Kaito Sentai Lupinranger VS Keisatsu Sentai Patranger posted the lowest first figures in recorded history for the franchise. Super Sentai is reported to have made 1.4 billion yen in the first quarter with forecasts of 3.0 billion yen in the first half and a full year forecast of 10.5 billion yen.

Ultraman is reported as having made 0.7 billion yen in its first quarter with a forecast of 2.5 billion yen for the first half of the financial year, making it just the second time Ultraman will have outperformed a Super Sentai series. The current show, Ultraman R/B, did not start until June, meaning its first quarter is predicted as having sold 1.8 billion yen.

Kamen Rider improved over the previous year with 4.0 billion yen sold in its first quarter and a prediction of 10.0 billion yen for the first half of the air, although it is still expected to under-perform compared to last year with 22.5 billion yen predicated against last year’s 24.8 billion yen.

Elsewhere, Pretty Cure improved in its first quarter, with 2.5 billion yen over last year’s 1.8 billion yen.

Source: Bandai Namco